Drug interaction Study Guide

📖 Core Concepts Drug Interaction – alteration of a drug’s action when taken with foods, beverages, or other drugs. Drug‑Food vs Drug‑Drug – food (e.g., grapefruit) can change metabolism; drug‑drug involves two pharmacologic agents. Pharmacodynamic (PD) Interaction – occurs at the target site (receptor or signaling pathway). Pharmacokinetic (PK) Interaction – alters ADME (Absorption, Distribution, Metabolism, Excretion). Additive, Synergistic, Antagonistic – quantitative descriptors of combined effect. Cytochrome P450 (CYP) Enzymes – major metabolic family (CYP1, CYP2, CYP3); key isoforms: CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4. Enzyme Inhibition vs Induction – inhibition ↑ drug A levels; induction ↓ drug A levels. Herb‑Drug Interaction – usually via CYP induction/inhibition or P‑glycoprotein modulation (e.g., St. John’s wort). Risk Enhancers – advanced age, genetic polymorphisms, hepatic/renal disease, narrow therapeutic index drugs. --- 📌 Must Remember Additive: total effect = effect₁ + effect₂. Synergistic: total effect > sum of individual effects. Antagonistic: total effect < sum of individual effects. Competitive antagonist → binds same receptor site → effect reversible with higher agonist concentration. Uncompetitive (irreversible) antagonist → covalently binds → effect not overcome by more agonist. Absorption ↓ when: ↑ intestinal motility, ↑ pH (antacids), chelation (Ca²⁺ + tetracyclines/fluoroquinolones). Grapefruit juice → inhibits intestinal P‑glycoprotein → ↑ bioavailability of P‑gp substrates. Protein‑binding competition matters clinically only if renal/hepatic function is impaired. CYP inhibition → ↑ substrate plasma concentration; CYP induction → ↓ substrate concentration. St. John’s wort = strong CYP3A4 & P‑gp inducer → ↓ levels of many drugs (e.g., cyclosporine, digoxin). Narrow therapeutic index drugs (digoxin, warfarin, insulin) = high‑risk for clinically significant interactions. --- 🔄 Key Processes Absorption‑Based Interaction Change GI pH → alters drug ionisation → modifies passive diffusion. Chelation → non‑absorbable complex → ↓ plasma levels. Transport/Distribution Interaction Drug A displaces Drug B from albumin → ↑ free fraction of B → potential toxicity. Compensatory ↑ clearance unless organ function is compromised. Metabolism Interaction (CYP) Identify substrate → check if co‑administered drug is inhibitor or inducer of that CYP. Inhibition → longer half‑life, higher Cₘₐₓ. Induction → shorter half‑life, lower Cₘₐₓ. Excretion Interaction Only free drug filtered → protein‑binding changes affect renal clearance. Urine pH shift → ion trapping or enhanced secretion of weak acids/bases. Herb‑Drug Interaction Herb component → induces/inhibits CYP3A4 or P‑gp → alters clearance of co‑administered drug. --- 🔍 Key Comparisons Additive vs Synergistic vs Antagonistic Additive: Effect = A + B. Synergistic: Effect > A + B. Antagonistic: Effect < A + B. Competitive vs Uncompetitive Antagonism Competitive: Same binding site, reversible, overcome by higher agonist. Uncompetitive: Irreversible binding, effect persists despite agonist concentration. Drug‑Drug vs Drug‑Food Interaction Drug‑Drug: Usually PD or PK overlap (same receptor or same CYP). Drug‑Food: Often PK (pH change, enzyme inhibition by food components). Enzyme Inhibition vs Induction Inhibition: ↑ substrate level, risk of toxicity. Induction: ↓ substrate level, risk of therapeutic failure. Protein‑Binding Competition vs Clinically Significant Interaction Binding competition: often compensated by clearance. Significant: when organ dysfunction limits compensatory clearance. --- ⚠️ Common Misunderstandings “All protein‑binding interactions are dangerous.” – Only clinically relevant when clearance is impaired. “Antagonists always reduce drug effect to zero.” – Competitive antagonists can be overcome; uncompetitive antagonists may only partially block. “Herbal supplements are always safe.” – Many (e.g., St. John’s wort) strongly induce CYP3A4 → major PK changes. “If two drugs act on different receptors, they cannot interact.” – Heterodynamic PD interactions occur via shared downstream pathways. “Grapefruit only affects metabolism.” – It also inhibits intestinal P‑glycoprotein, altering drug transport. --- 🧠 Mental Models / Intuition “Key‑Lock” Model: Agonist = key that turns the lock (receptor); antagonist = key that blocks the lock; competitive = wrong key in same slot, uncompetitive = broken key glued to lock. “Traffic Jam” Model for CYP: Enzyme = road; inhibitor = roadblock (cars pile up → higher drug levels); inducer = extra lanes (cars flow faster → lower drug levels). “pH River” Model: Acidic drug prefers low‑pH water; raising pH = shallow river → drug slips out, reducing absorption. --- 🚩 Exceptions & Edge Cases Protein‑binding competition becomes important in renal/hepatic failure or when one drug has very high affinity for albumin. Grapefruit effect is limited to drugs that are P‑gp substrates and CYP3A4 metabolized; not universal. St. John’s wort induction may persist weeks after discontinuation due to enzyme turnover. Partial agonists can act as functional antagonists in the presence of a full agonist (they occupy receptors but produce weaker response). --- 📍 When to Use Which Assess Interaction Type → PD? Look for shared receptor or signaling pathway (homodynamic vs heterodynamic). PK? Identify which ADME step is likely affected (absorption pH, transport protein, CYP, excretion). Choose Monitoring Strategy → Narrow‑TI drug → therapeutic drug monitoring (TDM) + dose adjustment. CYP substrate → check co‑administered inhibitors/inducers; consider alternative pathway or dose change. When to Adjust Dose vs Switch Drug → Minor PK change (≤20% Cₘₐₓ) → monitor. Major change (>50% Cₘₐₓ or known toxicity) → dose reduction or alternative agent. Herb‑Drug Decision → If patient uses St. John’s wort → avoid drugs with narrow TI metabolized by CYP3A4; consider alternative or hold herb. --- 👀 Patterns to Recognize Same CYP Isozyme → High Interaction Risk (e.g., two CYP3A4 substrates). Acid‑labile drugs + antacids → ↓ absorption (look for “requires acidic environment”). Chelation potential → tetracyclines or fluoroquinolones + calcium‑rich foods. Drugs with steep dose‑response curves + any PK change → disproportionate clinical effect. Elderly + polypharmacy → exponential rise in interaction probability. --- 🗂️ Exam Traps Distractor: “All P‑glycoprotein inhibitors increase drug toxicity.” Why wrong: Only if the drug’s efficacy relies on P‑gp efflux; many drugs are not P‑gp substrates. Distractor: “Competitive antagonists are always reversible.” Why tempting: By definition they compete, but some can have long residence times mimicking irreversibility. Distractor: “If a drug is highly protein‑bound, any co‑administered drug will cause toxicity.” Why wrong: Most binding shifts are compensated unless organ function is compromised. Distractor: “Herbal supplements only cause induction, never inhibition.” Why wrong: Some herbs (e.g., grapefruit juice) inhibit CYPs. Distractor: “Synergistic interactions always produce adverse effects.” Why wrong: Synergy can be therapeutic (e.g., drug‑combination chemotherapy). ---